Key Points

  • LRPAP1-autoantibodies are MIPI-independent markers for superior FFS and OS in MCL treated with immunochemotherapy.

Abstract

Low-density lipoprotein (LDL) receptor-related protein-associated protein 1 (LRPAP1) had been identified by B-cell receptor (BCR) expression cloning and subsequent protein array screening as a frequent and proliferation-inducing autoantigen of mantle cell lymphoma (MCL). Of interest, high-titered and light chain–restricted LRPAP1 autoantibodies were detected in 8 of 28 patients with MCL. In the present study, LRPAP1 autoantibodies in sera of patients treated within the Younger and Elderly trials of the European MCL Network were analyzed regarding frequency, association with disease characteristics, and prognostic impact. LRPAP1 autoantibodies were detected in 41 (13%) of 312 evaluable patients with MCL. These LRPAP1 autoantibodies belonged predominantly to the immunoglobulin G (IgG) class and were clonally light chain restricted (27 with κ light chains, 14 patients with λ light chains). Titers ranged between 1:400 and 1:3200. The presence of LRPAP1 autoantibodies was not significantly associated with any baseline clinical characteristic, however, it was associated with a superior 5-year probability for failure-free survival (FFS) of 70% (95% confidence interval [CI], 57% to 87%) vs 51% (95% CI, 44% to 58%), P = .0052; and for overall survival (OS) of 93% (95% CI, 85% to 100%) vs 68% (95% CI, 62% to 74%), P = .0142. LRPAP1-seropositive patients had a Mantle Cell Lymphoma International Prognostic Index–adjusted hazard ratio for FFS of 0.48 (95% CI 0.27-0.83, P = .0083) and for OS of 0.47 (95% CI 0.24-0.94, P = .032). LRPAP1 autoantibodies were frequently detected in a large cohort of MCL patients treated within prospective multicenter clinical trials. Our results suggest better outcomes for LRPAP1-autoantibody seropositive patients.

REFERENCES

1.
Swerdlow
SH
,
Campo
E
,
Pileri
SA
, et al
.
The 2016 revision of the World Health Organization classification of lymphoid neoplasms
.
Blood
.
2016
;
127
(
20
):
2375
-
2390
.
2.
Swerdlow
SH
,
Habeshaw
JA
,
Murray
LJ
,
Dhaliwal
HS
,
Lister
TA
,
Stansfeld
AG
.
Centrocytic lymphoma: a distinct clinicopathologic and immunologic entity. A multiparameter study of 18 cases at diagnosis and relapse
.
Am J Pathol
.
1983
;
113
(
2
):
181
-
197
.
3.
Tiemann
M
,
Schrader
C
,
Klapper
W
, et al;
European MCL Network
.
Histopathology, cell proliferation indices and clinical outcome in 304 patients with mantle cell lymphoma (MCL): a clinicopathological study from the European MCL Network
.
Br J Haematol
.
2005
;
131
(
1
):
29
-
38
.
4.
Williams
ME
,
Westermann
CD
,
Swerdlow
SH
.
Genotypic characterization of centrocytic lymphoma: frequent rearrangement of the chromosome 11 bcl-1 locus
.
Blood
.
1990
;
76
(
7
):
1387
-
1391
.
5.
Queirós
AC
,
Beekman
R
,
Vilarrasa-Blasi
R
, et al
.
Decoding the DNA methylome of mantle cell lymphoma in the light of the entire B cell lineage
.
Cancer Cell
.
2016
;
30
(
5
):
806
-
821
.
6.
Kienle
D
,
Kröber
A
,
Katzenberger
T
, et al
.
VH mutation status and VDJ rearrangement structure in mantle cell lymphoma: correlation with genomic aberrations, clinical characteristics, and outcome
.
Blood
.
2003
;
102
(
8
):
3003
-
3009
.
7.
Hadzidimitriou
A
,
Agathangelidis
A
,
Darzentas
N
, et al
.
Is there a role for antigen selection in mantle cell lymphoma? Immunogenetic support from a series of 807 cases
.
Blood
.
2011
;
118
(
11
):
3088
-
3095
.
8.
Walsh
SH
,
Thorsélius
M
,
Johnson
A
, et al
.
Mutated VH genes and preferential VH3-21 use define new subsets of mantle cell lymphoma
.
Blood
.
2003
;
101
(
10
):
4047
-
4054
.
9.
Saba
NS
,
Liu
D
,
Herman
SEM
, et al
.
Pathogenic role of B-cell receptor signaling and canonical NF-κB activation in mantle cell lymphoma
.
Blood
.
2016
;
128
(
1
):
82
-
92
.
10.
Myklebust
JH
,
Brody
J
,
Kohrt
HE
, et al
.
Distinct patterns of B-cell receptor signaling in non-Hodgkin lymphomas identified by single-cell profiling
.
Blood
.
2017
;
129
(
6
):
759
-
770
.
11.
Wang
ML
,
Rule
S
,
Martin
P
, et al
.
Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma
.
N Engl J Med
.
2013
;
369
(
6
):
507
-
516
.
12.
Kahl
BS
,
Spurgeon
SE
,
Furman
RR
, et al
.
A phase 1 study of the PI3Kδ inhibitor idelalisib in patients with relapsed/refractory mantle cell lymphoma (MCL)
.
Blood
.
2014
;
123
(
22
):
3398
-
3405
.
13.
Dreyling
M
,
Jurczak
W
,
Jerkeman
M
, et al
.
Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study
.
Lancet
.
2016
;
387
(
10020
):
770
-
778
.
14.
Tam
CS
,
Anderson
MA
,
Pott
C
, et al
.
Ibrutinib plus venetoclax for the treatment of mantle-cell lymphoma
.
N Engl J Med
.
2018
;
378
(
13
):
1211
-
1223
.
15.
Thurner
L
,
Hartmann
S
,
Fadle
N
, et al
.
LRPAP1 is a frequent proliferation-inducing antigen of BCRs of mantle cell lymphomas and can be used for specific therapeutic targeting
.
Leukemia
.
2019
;
33
(
1
):
148
-
158
.
16.
Korenberg
JR
,
Argraves
KM
,
Chen
XN
,
Tran
H
,
Strickland
DK
,
Argraves
WS
.
Chromosomal localization of human genes for the LDL receptor family member glycoprotein 330 (LRP2) and its associated protein RAP (LRPAP1)
.
Genomics
.
1994
;
22
(
1
):
88
-
93
.
17.
Herz
J
,
Goldstein
JL
,
Strickland
DK
,
Ho
YK
,
Brown
MS
.
39-kDa protein modulates binding of ligands to low density lipoprotein receptor-related protein/alpha 2-macroglobulin receptor
.
J Biol Chem
.
1991
;
266
(
31
):
21232
-
21238
.
18.
Williams
SE
,
Ashcom
JD
,
Argraves
WS
,
Strickland
DK
.
A novel mechanism for controlling the activity of alpha 2-macroglobulin receptor/low density lipoprotein receptor-related protein. Multiple regulatory sites for 39-kDa receptor-associated protein
.
J Biol Chem
.
1992
;
267
(
13
):
9035
-
9040
.
19.
Strickland
DK
,
Ashcom
JD
,
Williams
S
, et al
.
Primary structure of alpha 2-macroglobulin receptor-associated protein. Human homologue of a Heymann nephritis antigen
.
J Biol Chem
.
1991
;
266
(
20
):
13364
-
13369
.
20.
Orlando
RA
,
Farquhar
MG
.
Functional domains of the receptor-associated protein (RAP)
.
Proc Natl Acad Sci USA
.
1994
;
91
(
8
):
3161
-
3165
.
21.
Pott
C
,
Hoster
E
,
Beldjord
K
, et al
.
R-CHOP/R-DHAP compared to R-CHOP induction followed by high dose therapy with autologous stem cell transplantation induces higher rates of molecular remission in MCL: results of the MCL Younger Intergroup Trial of the European MCL Network [abstract]
.
Blood
.
2010
;
116
(
21
). Abstract 965.
22.
Pott
C
,
Hoster
E
,
Beldjord
K
, et al
.
R-CHOP/R-DHAP compared to R-CHOP induction followed by high dose therapy with autologous stem cell transplantation induces higher rates of molecular remission in MCL: results of the MCL Younger Intergroup Trial of the European MCL Network [abstract]
.
Blood
.
2010
;
116
(
21
). Abstract 965.
23.
Hermine
O
,
Hoster
E
,
Walewski
J
, et al;
European Mantle Cell Lymphoma Network
.
Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma Network
.
Lancet
.
2016
;
388
(
10044
):
565
-
575
.
24.
Kluin-Nelemans
HC
,
Hoster
E
,
Hermine
O
, et al
.
Treatment of older patients with mantle-cell lymphoma
.
N Engl J Med
.
2012
;
367
(
6
):
520
-
531
.
25.
Hoster
E
,
Dreyling
M
,
Klapper
W
, et al;
European Mantle Cell Lymphoma Network
.
A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma
.
Blood
.
2008
;
111
(
2
):
558
-
565
.
26.
Eskelund
CW
,
Dahl
C
,
Hansen
JW
, et al
.
TP53 mutations identify younger mantle cell lymphoma patients who do not benefit from intensive chemoimmunotherapy
.
Blood
.
2017
;
130
(
17
):
1903
-
1910
.
27.
Aukema
SM
,
Hoster
E
,
Rosenwald
A
, et al
.
P53 but not SOX11 IHC has prognostic value independent of MIPI and KI-67 in prospective trials of the European-MCL Network
.
Hematol. Oncol
.
2017
;
35
(
S2
):
139
-
140
.
28.
Dreyling
M
,
Hoster
E
,
Unterhalt
M
, et al
.
Clinical outcome of mantle cell lymphoma patients with high risk biology (high Ki-67, blastoid MCL, or high p53 expression) [abstract]
.
Blood
.
2019
;
134
(
suppl 1
). Abstract
3996
.
29.
Fernàndez
V
,
Salamero
O
,
Espinet
B
, et al
.
Genomic and gene expression profiling defines indolent forms of mantle cell lymphoma
.
Cancer Res
.
2010
;
70
(
4
):
1408
-
1418
.
30.
Nygren
L
,
Baumgartner Wennerholm
S
,
Klimkowska
M
,
Christensson
B
,
Kimby
E
,
Sander
B
.
Prognostic role of SOX11 in a population-based cohort of mantle cell lymphoma
.
Blood
.
2012
;
119
(
18
):
4215
-
4223
.
31.
Wang
M
,
Locke
FL
,
Munoz
J
, et al
.
ZUMA-2: phase 2 multicenter study evaluating efficacy of kte-C19 in patients with relapsed/refractory mantle cell lymphoma [abstract]
.
J Clin Oncol
.
2018
;
36
(
suppl 15
). Abstract TPS3102.
You do not currently have access to this content.

Sign in via your Institution

Sign In